公开(公告)号：AT270288T

公开(公告)日：2004-07-15

申请号：AT00932445

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Heterocyclic substituted aminoazacyclic compounds of the formula (I):Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

公开(公告)号：HU0202034A2

公开(公告)日：2002-10-28

申请号：HU0202034

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： DAANEN JEROME F ,  JI JIANGUO ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Heterocyclic substituted aminoazacyclic compounds of the formula (I):Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

公开(公告)号：HU0200332A2

公开(公告)日：2002-06-29

申请号：HU0200332

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  TOUPENCE RICHARD B

IPC: A61K31/00 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：SK16812001A3

公开(公告)日：2002-05-09

申请号：SK16812001

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Heterocyclic substituted aminoazacyclic compounds of the formula (I):Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

公开(公告)号：SK10692001A3

公开(公告)日：2002-01-07

申请号：SK10692001

申请日：2000-01-25

Applicant: ABBOTT LAB

Inventor： BUNNELLE WILLIAM H ,  CRISTINA DANIELA BARLOCCO ,  DAANEN JEROME F ,  DART MICHAEL J ,  MEYER MICHAEL D ,  RYTHER KEITH B ,  SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  TOUPENCE RICHARD B

IPC: A61K31/00 ,  A61K31/407 ,  A61K31/4355 ,  A61K31/4365 ,  A61K31/439 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/501 ,  A61K31/502 ,  A61P9/10 ,  A61P15/10 ,  A61P25/00 ,  A61P25/02 ,  A61P25/06 ,  A61P25/08 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P25/28 ,  A61P25/30 ,  C07D401/08 ,  C07D471/08 ,  C07D487/08 ,  C07D491/048 ,  C07D495/04 ,  C07D519/00 ,  A61K31/395

Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof wherein: V is selected from the group consisting of a covalent bond and CH2; W is selected from the group consisting of a covalent bond, CH2 and CH2CH2; X is selected from the group consisting of a covalent bond and CH2; Y is selected from the group consisting of a covalent bond, CH2 and CH2CH2; Z is selected from the group consisting of CH2 and CH2CH2, and CH2CH2CH2; L1 is selected from the group consisting of a covalent bond and (CH2)n; n is 1-5; R1 is selected from the group consisting of (a), (b), (c), (d), (e), (f), (g), (h), (i), (j), (k), and (l); R2 is selected from the group consisting of hydrogen, alkoxycarbonyl, alkyl, aminoalkyl, aminocarbonylalkyl, benzyloxycarbonyl, cyanoalkyl, dihydro-3-pyridinylcarbonyl, hydroxy, hydroxyalkyl, phenoxycarbonyl, and -NH2; are useful for controlling synaptic transmission in mammal.

公开(公告)号：AU733881B2

公开(公告)日：2001-05-31

申请号：AU5601098

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHEN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P

IPC: A61P25/04 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/485 ,  A61P25/28 ,  A61P29/00 ,  C07D205/04 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  A61K31/44

Abstract: The present invention relates to a method of controlling pain in mammals, including humans, comprising administering to a mammal or patient in need of treatment thereof selected compounds of formula (I) or a pharmaceutically acceptable salt thereof. The invention further relates to selected (R) and (S) compounds of formula (I) which are useful as analgesics as well as neuronal cell death preventors and anti-inflammatories.

公开(公告)号：HK1026416A1

公开(公告)日：2000-12-15

申请号：HK00104266

申请日：2000-07-11

Applicant: ABBOTT LAB

Inventor： WASICAK JAMES T ,  GARVEY DAVID S ,  HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B

IPC: A61P25/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  A61P25/00 ,  A61P43/00 ,  C07D487/04 ,  C07D ,  A61K

Abstract: 7a-Substituted hexahydro-1H-pyrrolizine compounds having the formula wherein A is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to selectively control synaptic transmission in mammals.

公开(公告)号：AU5016600A

公开(公告)日：2000-12-12

申请号：AU5016600

申请日：2000-05-15

Applicant: ABBOTT LAB

Inventor： SCHRIMPF MICHAEL R ,  SIPPY KEVIN B ,  DAANEN JEROME F ,  RYTHER KEITH B ,  JI JIANGUO

IPC: C07D491/048 ,  A61K31/00 ,  A61K31/4427 ,  A61K31/4439 ,  A61K31/4545 ,  A61K45/00 ,  A61P25/00 ,  A61P25/04 ,  A61P25/16 ,  A61P25/18 ,  A61P25/24 ,  A61P25/28 ,  C07D401/04 ,  C07D495/04

Abstract: Heterocyclic substituted aminoazacyclic compounds of the formula (I):Z-R3, wherein Z is a defined aminoazacycle and R3 is a defined heterocycle moiety, pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

公开(公告)号：CZ9902048A3

公开(公告)日：2000-01-12

申请号：CZ204899

申请日：1997-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  ARNERIC STEPHAN P ,  BAI HAO ,  DART MICHAEL J ,  LIN NAN-HORNG ,  SULLIVAN JAMES P ,  WASICAK JAMES T ,  EHRLICH PAUL P ,  LYNCH JOHN K ,  OR YAT SUN ,  RYTHER KEITH B

IPC: A61K31/44 ,  A61P25/04 ,  C07D205/04 ,  C07D401/12

公开(公告)号：HK1011866A1

公开(公告)日：1999-07-23

申请号：HK98113169

申请日：1998-12-10

Applicant: ABBOTT LAB

Inventor： HOLLADAY MARK W ,  LIN NAN-HORNG ,  RYTHER KEITH B ,  HE YUN

IPC: A61K31/00 ,  A61K31/44 ,  A61K31/4427 ,  A61K31/4439 ,  A61P25/00 ,  A61P25/04 ,  C07D401/12 ,  C07D403/12 ,  C07D417/12 ,  C07D ,  A61K

Abstract: Novel 3-pyridyloxymethyl heterocyclic ether compounds having formula (I), wherein * is a chiral center and n, X, R , R , A andB are specifically defined, which are useful in controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions therof; and use of said compositions to selectively control synaptic transmission in mammals.